Inmune Bio INMB
NASDAQ INMB
$1.95 -0.01 (-0.51%)
At close: Sep 30, 2026 · 4:00 PM EDT

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023)

Updated

Inmune Bio (INMB) reported Total Non-Current Liabilities of $17.96 million for Q3 2023.

Analysis

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023) Analysis & Trends

At the end of FY2022, Inmune Bio posted Total Non-Current Liabilities of $21.14 million, up 7.2% from FY2021.

  • By year, Total Non-Current Liabilities came in at $19.72 million in FY2021.
  • The Q3 2023 figure ranks as the lowest quarterly Total Non-Current Liabilities since Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 105.99 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 106.45 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 80.25 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -967.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 81.11 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 36.04 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 100.86 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 5.92 Bn
10 Inmune Bio 54.20 Mn -38.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 17.96 Mn
Dec 31, 2022 21.14 Mn
Mar 31, 2022 18.71 Mn
Dec 31, 2021 19.72 Mn
Sep 30, 2021 19.17 Mn
Jun 30, 2021 17.31 Mn
API Access

Inmune Bio Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=INMB&period=max&api_key=YOUR_API_KEY